Published on 06/12/2025
Building robust use scenarios and task analyses for human factors studies
Context
Human factors and operator qualification are critical elements in the design and development of pharmaceutical products and medical devices. The primary goal is to optimize human interaction with systems to minimize the potential for use errors. Use-error risk analysis is a vital component of human factors studies, enabling the identification and mitigation of risks associated with the interaction between users and devices. As per regulatory guidelines, performing thorough use-error risk analyses and task mapping is essential to demonstrate compliance with ISO 14971 and related regulations.
Legal/Regulatory Basis
In the United States, the Food and Drug Administration (FDA) governs the requirements for human factors studies through its guidance documents and regulations. The core regulations that apply include:
- 21 CFR Part 820 – Quality System Regulation
- 21 CFR Part 830 – Unique Device Identification
- 21 CFR Part 803 – Medical Device Reporting
The FDA emphasizes the importance of human factors in device design through several guidance documents, most notably the “Applying Human Factors and Usability Engineering to Medical Devices” guidance.
In the European Union, the guidelines are primarily derived from the Medical Device Regulation (MDR) and
The UK follows similar regulations post-Brexit, guided by both UK Medical Device Regulations and the Health and Safety Executive. The MHRA, the regulatory authority for medical devices in the UK, also provides guidance aligning with ISO standards.
Documentation
Proper documentation is essential for the validation of human factors studies. The following documents are typically required:
- Use-Error Risk Analysis Report – Summarizes the findings of risk assessments, including identified hazards and control measures.
- Task Analysis Documentation – Details the tasks performed by users and any potential for use errors.
- Usability Test Plans and Reports – Outlines the strategy for usability testing and summarizes results, including any identified use errors.
- Use Scenarios – Describes realistic contexts in which the product will be used.
All documentation should maintain clarity, be structured logically, and reference applicable regulations and standards, such as ISO 14971 and IEC 62366.
Review/Approval Flow
The review and approval process for human factors studies involves several key stages:
1. Planning Phase
Define objectives, create a project plan, and establish timelines. It is essential to align the scope of the studies with regulatory expectations.
2. Conducting Usability Tests
Implement usability testing at various stages, employing real users to identify use errors and gather feedback. The tests should adhere to established protocols.
3. Data Analysis
Analyze usability testing results to identify trends, patterns, or specific issues. Assess risks and categorize errors based on severity and likelihood.
4. Reporting
Compile a comprehensive report that encompasses the findings, conclusions, and recommendations for mitigation of identified risks.
5. Submission to Regulatory Authorities
Present the documentation and report in accordance with agency guidelines. Make sure to articulate the rationale behind design decisions and risk controls.
Common Deficiencies
Despite thorough planning, regulatory submissions may encounter deficiencies. Some common deficiencies include:
- Lack of Comprehensive Risk Analysis – Inadequate identification or evaluation of use errors.
- Poor Task Mapping – Failure to document critical user steps or reliance solely on hypothetical scenarios rather than realistic use conditions.
- Inadequate Justification of Design Changes – Insufficient explanation for changes made post-user testing or lack of acknowledgment of identified use errors.
- Non-compliance with Standards – Not aligning with ISO 14971 and regulatory expectations can lead to rejection of applications.
RA-specific Decision Points
When to File as Variation vs. New Application
In regulatory affairs, professionals must determine the pathway for submitting changes. The decision will hinge on several factors:
- Nature of Changes: If changes affect the intended use, design, or critical user interactions, a new application may be warranted.
- Impact on Safety and Efficacy: Changes that significantly impact the product’s risk profile typically necessitate a new submission.
- Regulatory Guidance: Consult the latest guidance from the FDA, EMA, and MHRA, as they provide clarity on how to categorize changes.
How to Justify Bridging Data
Bridging data may be required when differences in use conditions exist, or when prior studies are conducted with older versions of a product. Justification can be structured around:
- Previous Findings: Cite past studies that demonstrate safety and usability under similar contexts.
- Scientific Rationale: Provide scientific reasoning or literature that supports the applicability of existing data.
- Similarity in User Interaction: Demonstrate similarity in critical user steps that minimizes the need for extensive new data.
Conclusion
Effective human factors risk analyses and proper task mapping are essential for ensuring the safety and usability of pharmaceutical products and medical devices. Regulatory professionals should remain cognizant of the stringent expectations set forth by the FDA, EMA, and MHRA while ensuring all documentation, processes, and determinations are meticulously validated and submitted. By understanding the legal context, documentation requirements, approval flows, and common deficiencies, regulatory affairs professionals can enhance compliance and drive successful submissions in today’s complex regulatory landscape.